 |
|
|
| |
Functional cure rate in chronic hepatitis B virus infected participants receiving elebsiran and pegylated interferon alfa: final results from the phase 2 ENSURE study (BRII-179)
|
| |
| |
EASL 2026 May 27-30 Barcelona
Grace Lai-Hung Wong1, Man-Fung Yuen2, Bingliang Lin3, Mark Douglas4, Chong Zhu5, Ke Cao5, Alex Tian5, Xiaofei Chen5, Qing Zhu6, David Margolis6, Zhi Hong6, Jidong Jia7
1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong; 2 Department of Medicine, School of Clinical Medicine, The University of Hong Kong; 3 The Third Affiliated Hospital, Sun Yat- Sen University; 4 The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital; 5 Brii Biosciences (Beijing) Co. Limited; 6 Brii Biosciences, Inc.; 7 Liver Research Center, Beijing Friendship Hospital, Capital Medical University
|
| |
|
|
|
|
|
